What to expect in the AGIOS PHARMACEUTICALS, INC. interview process

Based on publicly available sources, Agios Pharmaceuticals (NASDAQ: AGIO) is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, with operations spanning 6 countries including the United States, India, Switzerland, Spain, and the United Kingdom. Founded in 2007 and publicly traded since 2013, the organization focuses on cellular metabolism and rare disease treatments, particularly classical hematology, with key products like Pyrukynd (mitapivat) and an active clinical pipeline.

Workforce and hiring data indicate that Agios operates with a specialized, mid-sized headcount. Revelio Labs workforce intelligence notes approximately 523 total employees worldwide as of March 2026, representing a growth of roughly 19.3% from 439 employees in 2023. While the company maintains a global footprint, hiring activity has seen adjustments: active job postings dropped to 26 in 2026, marking a 63.2% decline compared to 2025.

Leadership includes CEO Brian M. Goff and Chief Medical Officer Dr. Sarah Gheuens, alongside scientific co-founders such as Dr. Lewis Clayton Cantley. The company engages in regulatory navigation with agencies like the FDA and maintains strategic partnerships, such as collaborations with Oscotec and Avanzanite, to drive its rare disease portfolio forward. Historical H-1B visa, E-3 visa, and PERM greencard applications indicate that the company sponsors international talent for specialized roles within its biopharma operations.